Thanks Karl for providing some very good perspectives on value. We would debate one point: with 571 efficacy studies – many of them RCTs – showing quantitative health outcomes benefits, many of which can be mapped to economic benefits – it’s hard to buy the notion that there isn’t plenty of data out there. In today’s Digital Health climate, I think I’d have a hard time taking any app without clinical data seriously unless I‎t has breakthrough technology.